943320-63-6

Basic information

• Product Name: [(R)-1-(4-amino-2-trifluoromethyl-benzyl)-pyrrolidin-3-yl]-dimethyl-amine
• Synonyms: [(R)-1-(4-amino-2-trifluoromethyl-benzyl)-pyrrolidin-3-yl]-dimethyl-amine
• CAS NO: 943320-63-6
• Molecular Weight: 287.328
• Mol File: 943320-63-6.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: [(R)-1-(4-amino-2-trifluoromethyl-benzyl)-pyrrolidin-3-yl]-dimethyl-amine(CAS DataBase Reference)
• NIST Chemistry Reference: [(R)-1-(4-amino-2-trifluoromethyl-benzyl)-pyrrolidin-3-yl]-dimethyl-amine(943320-63-6)
• EPA Substance Registry System: [(R)-1-(4-amino-2-trifluoromethyl-benzyl)-pyrrolidin-3-yl]-dimethyl-amine(943320-63-6)

Safety Data

• Hazardous Substances Data: 943320-63-6(Hazardous Substances Data)

Upstream product

• 65934-74-9 3-(trifluoromethyl)-4-methylaniline 
• 1408000-39-4 tert-butyl N-[4-methyl-3-(trifluoromethyl)phenyl]carbamate 
• 1408000-40-7 tert-butyl N-[4-(bromomethyl)-3-(trifluoromethyl)phenyl]carbamate 
• 89976-12-5 1-methyl-4-nitro-2-(trifluoromethyl) benzene 
• 694499-22-4 1-(bromomethyl)-4-nitro-2-(trifluoromethyl) benzene 
• 943320-62-5 dimethyl-[(R)-1-(4-nitro-2-trifluoromethyl-benzyl)-pyrrolidin-3-yl]-amine 

Downstream Products

• 1408000-43-0 (R)-3-azido-N-(4-((3-(dimethylamino)pyrrolidin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-4-methylbenzamide 
• 1408000-03-2 C₃₀H₃₀F₃N₉O 

Relevant articles and documents

ISOQUINOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES

The present invention discloses compounds according to Formula (I) wherein R1, R2, R3, L1, L2, and L3 are as defined herein. The present invention relates to compounds inhibiting discoidin domain receptors (DDRs), methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of fibrotic diseases, inflammatory diseases, respiratory diseases, autoimmune diseases, metabolic diseases, cardiovascular diseases, and/or proliferative diseases by administering a compound of the invention.

NOVEL INHIBITORS OF MAP4K1

The invention relates to novel inhibitors of MAP4K1 (HPK1) useful for the treatment of diseases or disorders characterised by dysregulation of the signal transduction pathways associated with MAPK activation, including hyperproliferative diseases, diseases of immune system dysfunction, inflammatory disorders, neurological diseases, and cardiovascular diseases. The invention further relates to pharmaceutical compositions comprising the same and methods of treatment of said diseases and disorders. The inhibitors are of formula (I) wherein the definitions for A, D, E, F, R5, R6, R7, Z, ring Q, n, x and y are as given in the application.

METHODS AND COMPOSITIONS FOR RAF KINASE MEDIATED DISEASES

The invention discloses methods and compositions for treating or preventing RAF kinase mediated diseases or conditions by administering a compound of Formula 1: or a pharmaceutically acceptable salt, solvate or hydrate thereof, wherein the variables are defined as herein.